CAPTRUST Financial Advisors
MYOV

CAPTRUST Financial Advisors’s Myovant Sciences Ltd. MYOV Stock Holding History

CAPTRUST Financial Advisors’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-26,133
Closed -$705K – 2406
2022
Q4 		$705K Sell
26,133
-44,000
-63% -$1.16M ﹤0.01% 1157
2022
Q3 		$1.26M Sell
70,133
-100
-0.1% -$1.6K 0.01% 831
2022
Q2 		$873K Hold
70,233
– – 0.01% 902
2022
Q1 		$936K Buy
70,233
+100
+0.1% +$1.34K 0.01% 869
2021
Q4 		$1.09M Hold
70,133
– – 0.01% 782
2021
Q3 		$1.57M Buy
70,133
+25,133
+56% +$552K 0.01% 586
2021
Q2 		$1.02M Buy
45,000
+1,000
+2% +$21K 0.01% 709
2021
Q1 		$906K Buy
44,000
+1,210
+3% +$27.5K 0.01% 729
2020
Q4 		$1.18M Buy
42,790
+2,750
+7% +$53.5K 0.02% 562
2020
Q3 		$560K Buy
40,040
+16,000
+67% +$298K 0.01% 684
2020
Q2 		$484K Buy
24,040
+4,040
+20% +$55K 0.01% 718
2020
Q1 		$147K Hold
20,000
– – ﹤0.01% 973
2019
Q4 		$295K Buy
+20,000
New +$202K ﹤0.01% 851

Other funds holding MYOV

HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

CAPTRUST Financial Advisors's MYOV Position: Q1 2023 in Review

CAPTRUST Financial Advisors sold out of Myovant Sciences Ltd. (MYOV) in Q1 2023, closing a stake of 26,133 shares — an estimated $705K sold.

CAPTRUST Financial Advisors first reported a position in MYOV in Q4 2019 and held it in 13 quarters. The position peaked at $1.57M in Q3 2021. 2 funds tracked by Wall St. Rank hold MYOV as of Q1 2023.

  • CAPTRUST Financial Advisors reported no remaining Myovant Sciences Ltd. position as of Q1 2023 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 26,133 Myovant Sciences Ltd. shares in Q1 2023, an estimated $705K.
  • CAPTRUST Financial Advisors first reported a position in Myovant Sciences Ltd. in Q4 2019 and held it in 13 quarters.
  • CAPTRUST Financial Advisors's Myovant Sciences Ltd. position peaked at $1.57M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2023.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2023, filed 15 May 2023.